Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Prospective Trial of Metformin - Chemoprevention Role

Not Applicable

Withdrawn

Conditions: Colorectum

Interventions: Drug: Metformin ER
Other: Placebo

First Posted Date: 2012-03-12

Last Posted Date: 2013-04-05

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01550900

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

Phase 1

Terminated

Conditions: Advanced Cancers

Interventions: Drug: Pazopanib
Drug: Crizotinib (Xalkori)
Drug: Pemetrexed

First Posted Date: 2012-03-08

Last Posted Date: 2021-09-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 178

Registration Number: NCT01548144

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: Azacytidine
Drug: GM-CSF

First Posted Date: 2012-03-02

Last Posted Date: 2014-04-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT01542684

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Natural History of Lung Nodules Seen on CT Scans From Participants at High-Risk of Developing Lung Cancer

Completed

Conditions: Lung Cancer
Precancerous Condition

Interventions: Other: medical chart review
Procedure: computed tomography
Procedure: computer-aided detection/diagnosis

First Posted Date: 2012-02-29

Last Posted Date: 2013-01-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 320

Registration Number: NCT01540552

Locations: 🇮🇹
European Institute of Oncology, Milan, Italy

Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)

Phase 2

Completed

Conditions: Infection

Interventions: Drug: Antimicrobial Solution

First Posted Date: 2012-02-27

Last Posted Date: 2016-04-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT01539343

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Y Zevalin
Drug: In Zevalin
Drug: Rituxan
Drug: BCNU
Drug: VP -16
Drug: Ara-C
Drug: Melphalan
Procedure: Stem Cell Infusion
Drug: G-CSF

First Posted Date: 2012-02-24

Last Posted Date: 2014-09-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT01538472

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

Phase 3

Completed

Conditions: Cancer of the Cervix

Interventions: Drug: Granisetron
Drug: Ondansetron
Behavioral: Questionnaires
Behavioral: Study Drug Diary

First Posted Date: 2012-02-22

Last Posted Date: 2021-06-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 76

Registration Number: NCT01536392

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Lyndon B. Johnson General Hospital, Houston, Texas, United States

Erlotinib in Combination With Pralatrexate in Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Cancers
Solid Tumors

Interventions: Drug: Erlotinib
Drug: Pralatrexate

First Posted Date: 2012-02-13

Last Posted Date: 2016-07-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 72

Registration Number: NCT01532011

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

Phase 1

Completed

Conditions: Myeloma

Interventions: Drug: Lenalidomide
Drug: Bortezomib
Drug: Siltuximab
Drug: Dexamethasone
Behavioral: Questionnaires

First Posted Date: 2012-02-13

Last Posted Date: 2015-06-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT01531998

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Phase 1

Completed

Conditions: Advanced Malignant Neoplasm
Refractory Malignant Neoplasm
BRAF Gene Mutation
Metastatic Malignant Neoplasm
Recurrent Malignant Neoplasm

Interventions: Drug: Crizotinib
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis
Drug: Sorafenib Tosylate
Drug: Vemurafenib

First Posted Date: 2012-02-10

Last Posted Date: 2021-01-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT01531361

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy